- Home
- CMPS vs EVMN Comparison
CMPS vs EVMN Comparison
Compare CMPS & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | EVMN |
|---|---|---|
| Founded | 2020 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.7M | 892.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMPS | EVMN |
|---|---|---|
| Price | $6.14 | $24.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $27.14 | ★ $44.17 |
| AVG Volume (30 Days) | ★ 4.4M | 303.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $13.89 |
| 52 Week High | $8.90 | $33.20 |
Technical Indicators
Market Signals| Indicator | CMPS | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 51.41 |
| Support Level | $5.95 | $15.25 |
| Resistance Level | $7.02 | $33.20 |
| Average True Range (ATR) | 0.46 | 2.29 |
| MACD | -0.12 | -0.50 |
| Stochastic Oscillator | 3.82 | 43.20 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.